#5/A
7-23-01
PATENT M.L.
Docket No. 255.0004 0101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Mark A. Sheridan et al.	Group Art Unit:	1651
Serial No.:	09/727,739	Examiner:	Unknown
Filed:	December 1, 2000	Confirmation No.:	4181
For:	SOMATOSTATINS AND METHODS		

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington D.C. 20231

Sir:

Prior to taking up the above-identified patent application for examination, please enter the following amendments.

In The Specification

Please replace the paragraph at page 20, line 12 to page 21, line 9, with the following rewritten paragraph. Per 37 C.F.R §1.121, this paragraph is also shown in Appendix A, page A1, with notations to indicate the changes made.

A two-phase rapid amplification of cDNA ends (RACE) PCR-based approach (Fig. 4) was used for the isolation and characterization of selected cDNA sequences as described previously (Moore et al., Gen. Comp. Endocrinol., 98, 253-261 (1995). In phase I, endogenous poly-A RNA was reverse transcribed from 15 µg of trout pancreatic total RNA with Superscript II reverse transcriptase (Gibco/BRL, Gaithersburg, MD) and a 37 nucleotide antisense adapter primer 5'-GGCCACGCGTCGACTAGTAC$(T)_{17}$-3' (SEQ ID NO:22) (Gibco/BRL). Five microliters of the reverse transcription reaction were used as template for 3'-RACE PCR with a 21-base somatostatin gene-specific primer 5'-AAGAACTTCTTCTGGAAGAC-3' (GSP-1; SEQ ID NO:25) and the universal amplification primer 5'-CUACUACUACUAGGCCACGCGTCGACTAGTAC-3'(UAP; SEQ ID NO:23). After an initial denaturation cycle of 94°C for 5 minutes, 35 PCR

A1 cont